Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19261853 | COMPOSITIONS AND COMPOUNDS CONTAINNG KETONE BODIES AND/OR KETONE BODY PRECURSORS AND ONE OR MORE AMINO ACIDS | July 2025 | December 2025 | Allow | 6 | 1 | 0 | No | No |
| 19258578 | PHARMACEUTICAL COMPOSITIONS OF NILOTINIB | July 2025 | January 2026 | Allow | 6 | 1 | 0 | No | No |
| 19227609 | METHOD FOR TREATING HIV WITH CABOTEGRAVIR AND RILPIVIRINE | June 2025 | January 2026 | Allow | 8 | 1 | 0 | No | No |
| 19227593 | METHOD FOR TREATING HIV WITH CABOTEGRAVIR AND RILPIVIRINE | June 2025 | January 2026 | Allow | 8 | 1 | 0 | No | No |
| 19206909 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF EDARAVONE AND METHOD OF ADMINISTERING SAME | May 2025 | October 2025 | Allow | 5 | 1 | 0 | No | No |
| 19205979 | APPLICATION OF GLYCEROL MONODECANOATE IN PREPARATION OF HYPOGLYCEMIC DRUG OR FUNCTIONAL FOOD | May 2025 | October 2025 | Allow | 5 | 1 | 0 | No | No |
| 19059754 | Testosterone Dodecanoate Compositions and Methods | February 2025 | November 2025 | Allow | 9 | 2 | 0 | No | No |
| 19030399 | AMINO ACID COMPOSITIONS | January 2025 | September 2025 | Allow | 8 | 1 | 0 | Yes | No |
| 19030439 | AMINO ACID COMPOSITIONS | January 2025 | September 2025 | Allow | 8 | 1 | 0 | No | No |
| 19021386 | METHOD FOR TREATING A DISORDER | January 2025 | August 2025 | Allow | 7 | 1 | 0 | No | No |
| 19008588 | DIETARY GLYCINE AND SERINE RESTRICTION FOR CANCER TREATMENT | January 2025 | June 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19005921 | USE OF TYROSOL AS A PHYSIOLOGICAL ENHANCER OF CREATINE AND ITS APPLICATION IN CONTINUOUS HIGH INTENSITY EXERCISE | December 2024 | July 2025 | Allow | 6 | 2 | 0 | No | No |
| 18932667 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF EDARAVONE AND METHOD OF ADMINISTERING SAME | October 2024 | April 2025 | Allow | 5 | 1 | 0 | No | No |
| 18924252 | Oral (17-ß)-3-Oxoandrost-4-EN-17-YL Tridecanoate Therapy | October 2024 | January 2025 | Allow | 3 | 1 | 0 | No | No |
| 18855563 | INTRANASAL ADMINISTRATION OF N-ACETYLCYSTEINE AND USES THEREOF | October 2024 | December 2025 | Allow | 14 | 1 | 0 | No | No |
| 18853657 | ACETYL SALICYLIC ACID COMPOSITION FOR INTRAVENOUS ADMINISTRATION, ITS STORAGE, PRODUCTION AND USE | October 2024 | June 2025 | Allow | 8 | 1 | 0 | No | No |
| 18898132 | GAMMA-HYDROXYBUTYRATE COMPOSITIONS HAVING IMPROVED PHARMACOKINETICS IN THE FED STATE | September 2024 | March 2025 | Allow | 5 | 1 | 0 | No | No |
| 18790828 | Dosage Regimen | July 2024 | April 2025 | Allow | 9 | 1 | 0 | No | No |
| 18751014 | PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER | June 2024 | February 2025 | Allow | 8 | 1 | 0 | No | No |
| 18680287 | ESKETAMINE FOR THE TREATMENT OF DEPRESSION | May 2024 | March 2025 | Abandon | 9 | 1 | 0 | No | No |
| 18670619 | EFFECTIVE TREATMENT OF DEPRESSION IN PATIENTS HAVING IMPAIRED LEARNING AND/OR MEMORY OR CERTAIN EEG CHARACTERISTICS WITH A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT | May 2024 | April 2025 | Abandon | 11 | 2 | 0 | No | No |
| 18595759 | METHODS OF USING FACTOR B INHIBITORS | March 2024 | August 2025 | Allow | 18 | 1 | 0 | No | No |
| 18435109 | PRODRUGS OF L-BHDU AND METHODS OF TREATING VIRAL INFECTIONS | February 2024 | June 2025 | Allow | 17 | 1 | 0 | No | No |
| 18426914 | SERINE PROTEASE INHIBITOR FOR TREATING CORONAVIRUS INFECTION | January 2024 | August 2025 | Allow | 19 | 1 | 0 | No | No |
| 18419354 | NOVEL EBSELEN ANALOGUES LOADED NANOEMULSION | January 2024 | August 2024 | Allow | 7 | 1 | 0 | No | No |
| 18416811 | COMPOSITION COMPRISING A DIINDOLYLMETHANE AND A RETINOID TO TREAT A SKIN CONDITION | January 2024 | September 2025 | Allow | 20 | 2 | 0 | No | No |
| 18409208 | REDUCED DOSE METAXALONE FORMULATIONS | January 2024 | July 2025 | Allow | 18 | 1 | 0 | No | No |
| 18405593 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | January 2024 | June 2025 | Allow | 18 | 1 | 0 | No | No |
| 18403027 | TREATMENT AND DIAGNOSIS OF MELANOMA | January 2024 | August 2025 | Allow | 20 | 1 | 0 | No | No |
| 18394155 | COMPOSITION COMPRISING COMBINATION OF RAPAMYCIN AND METFORMIN AND USE THEREOF FOR TREATING NEURODEGENERATIVE DISEASES | December 2023 | May 2025 | Allow | 17 | 1 | 0 | No | No |
| 18390000 | METHOD OF REDUCING PULMONARY EXACERBATIONS IN RESPIRATORY DISEASE PATIENTS | December 2023 | October 2025 | Allow | 22 | 1 | 0 | No | No |
| 18545858 | Lipid Formulations for Delivery of Messenger RNA | December 2023 | December 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18534800 | COT MODULATORS AND METHODS OF USE THEREOF | December 2023 | July 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18528397 | COMPOSITIONS AND METHODS FOR MODULATING HEXIM1 EXPRESSION | December 2023 | July 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18524947 | SOLID FORMS OF A DUAL RAF/MEK INHIBITOR | November 2023 | September 2025 | Allow | 21 | 1 | 0 | No | No |
| 18523772 | METHOD TO ALLEVIATE THE SYMPTOMS OF PMS | November 2023 | February 2025 | Allow | 14 | 0 | 0 | No | No |
| 18519801 | STABLE TREPROSTINIL PRODRUGS | November 2023 | August 2025 | Allow | 20 | 2 | 0 | No | No |
| 18511262 | ATHLETIC PERFORMANCE ENHANCEMENT COMPOSITION USING MENTHOL | November 2023 | July 2025 | Allow | 20 | 1 | 0 | No | No |
| 18502543 | TREATMENT METHODS HAVING REDUCED DRUG-RELATED TOXICITY AND METHODS OF IDENTIFYING THE LIKELIHOOD OF PATIENT HARM FROM PRESCRIBED MEDICATIONS | November 2023 | July 2025 | Allow | 21 | 1 | 0 | No | No |
| 18500175 | TOPICAL FERTILITY PROMOTING PRODUCT AND MANUFACTURING METHOD | November 2023 | May 2025 | Allow | 18 | 1 | 0 | No | No |
| 18484823 | SULCARDINE ADMINISTRATION FOR TREATMENT OF ACUTE ATRIAL FIBRILLATION | October 2023 | July 2025 | Allow | 21 | 1 | 0 | No | No |
| 18478483 | COMBINATION THERAPY FOR TREATING CANCER | September 2023 | July 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18370116 | INTRANASAL PHARMACEUTICAL DOSAGE FORMS COMPRISING NALOXONE | September 2023 | July 2025 | Allow | 22 | 1 | 0 | No | No |
| 18468266 | PHARMACEUTICAL COMPOSITIONS OF NILOTINIB | September 2023 | May 2025 | Allow | 20 | 1 | 0 | No | No |
| 18242276 | COMPOSITIONS, DEVICES AND METHODS FOR TREATING OBSESSIVE-COMPULSIVE DISORDER | September 2023 | February 2026 | Abandon | 29 | 2 | 0 | No | No |
| 18240049 | Regimens of Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects | August 2023 | December 2025 | Allow | 27 | 2 | 0 | No | No |
| 18451520 | METHODS OF DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | August 2023 | June 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18365549 | TREATING SPONDYLOARTHRITIC AND PSORIATIC CONDITIONS WITH UPADACITINIB | August 2023 | June 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18364058 | NON-LINEAR DOSING OF MIRDAMETINIB | August 2023 | February 2025 | Allow | 18 | 1 | 0 | No | No |
| 18227210 | ADMINISTRATION OF BETA-HYDROXYBUTYRATE AND RELATED COMPOUNDS IN HUMANS FOR THE TREATMENT AND/OR PREVENTION OF RESPIRATORY ILLNESSES | July 2023 | April 2025 | Allow | 21 | 1 | 0 | No | No |
| 18345292 | USE OF AMBROXOL TO IMPROVE SKIN BARRIER FUNCTION | June 2023 | April 2025 | Allow | 22 | 1 | 0 | No | No |
| 18216307 | METHODS OF TREATMENT USING AN MTORC1 MODULATOR | June 2023 | April 2025 | Allow | 22 | 1 | 0 | No | No |
| 18343267 | ALK2 INHIBITORS FOR THE TREATMENT OF ANEMIA | June 2023 | April 2025 | Allow | 22 | 1 | 0 | No | No |
| 18341023 | FGFR2 INHIBITORS FOR THE TREATMENT OF CHOLANGIOCARCINOMA | June 2023 | March 2025 | Allow | 21 | 1 | 0 | No | No |
| 18336440 | Induced Expression of Brain Derived Neurotrophic Factor (BDNF) for Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental and/or Metabolic Diseases | June 2023 | April 2025 | Abandon | 22 | 0 | 1 | No | No |
| 18202790 | COMPOSITION, USES, AND METHODS OF TREATING SPINAL DISC DEGENERATION THROUGH SONIC HEDGEHOG SIGNALING PATHWAY | May 2023 | February 2026 | Allow | 32 | 2 | 1 | No | No |
| 18202704 | TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITON OF HSP90 | May 2023 | July 2025 | Allow | 26 | 2 | 0 | No | No |
| 18201106 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION CONTAINING SULFASALAZINE AND/OR A SULFASALAZINE ORGANIC SALT, PRODUCTION PROCESS AND USE | May 2023 | January 2025 | Allow | 19 | 1 | 0 | No | No |
| 18317881 | METHODS FOR THE ADMINISTRATION OF ILOPERIDONE | May 2023 | June 2025 | Abandon | 25 | 1 | 0 | No | No |
| 18252553 | NEUTROPHIL-TO-LYMPHOCYTE RATIO DECREASING AGENT | May 2023 | February 2026 | Allow | 33 | 1 | 0 | No | No |
| 18311715 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | May 2023 | March 2025 | Allow | 22 | 1 | 0 | No | No |
| 18310041 | TRIPTAN MICROPORATION DELIVERY SYSTEM | May 2023 | February 2025 | Allow | 22 | 1 | 0 | No | No |
| 18033993 | ANTI-VERTIGO COMPOUND AND PHARMACEUTICAL COMPOSITIONS THEREOF | April 2023 | March 2026 | Allow | 35 | 1 | 0 | No | No |
| 18305826 | Compositions And Methods For Treating Autism | April 2023 | June 2025 | Allow | 26 | 1 | 0 | No | No |
| 18136210 | GLUCOCORTICOID RECEPTOR MODULATORS TO TREAT CERVICAL CANCER | April 2023 | February 2025 | Allow | 22 | 1 | 0 | No | No |
| 18130749 | Therapeutic Uses of Compounds Having Combined Sert, 5-HT3 and 5-HT1a Activity | April 2023 | May 2025 | Abandon | 25 | 1 | 0 | No | No |
| 18247113 | COMPLEX CONTAINING WATER-SOLUBLE BETA-BLOCKER AND LECITHIN | March 2023 | February 2026 | Allow | 35 | 1 | 0 | No | No |
| 18028202 | Extended Release Pharmaceutical Formulation | March 2023 | December 2025 | Allow | 33 | 1 | 0 | No | No |
| 18246442 | COMPOSITIONS AND METHODS USING XANTHAN GUM TO STABILIZE AT LEAST ONE UROLITHIN IN AN AQUEOUS MATRIX | March 2023 | December 2025 | Allow | 33 | 1 | 0 | No | No |
| 18027608 | METHODS AND COMPOSITIONS TO TREAT AND PREVENT VIRAL INFECTIONS AND ACUTE RESPIRATORY DISTRESS SYNDROME | March 2023 | February 2026 | Allow | 34 | 1 | 0 | No | No |
| 18123080 | MACROCYCLES FOR USE IN TREATING DISEASE | March 2023 | February 2026 | Abandon | 35 | 1 | 0 | No | No |
| 18119679 | METHODS OF TREATING CHRONIC LYMPHOCYTIC LEUKEMIA USING 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE | March 2023 | May 2025 | Abandon | 26 | 1 | 0 | No | No |
| 18178941 | PREVENTION OR TREATMENT OF DISEASE STATES DUE TO METAL DIS-HOMEOSTASIS VIA ADMINISTRATION OF POSIPHEN TO HEALTHY OR SICK HUMANS | March 2023 | April 2025 | Allow | 26 | 1 | 0 | No | No |
| 18024572 | PYRROLIDINE COMPOUNDS TO TREAT XERODERMA PIGMENTOSUM | March 2023 | March 2026 | Abandon | 36 | 1 | 0 | No | No |
| 18116506 | MOLYBDENUM IMIDO ALKYL/ALLYL COMPLEXES FOR DEPOSITION OF MOLYBDENUM-CONTAINING FILMS | March 2023 | November 2025 | Allow | 33 | 1 | 0 | No | No |
| 18115593 | METHODS OF TREATING FIBROSIS | February 2023 | January 2025 | Allow | 23 | 1 | 0 | No | No |
| 18115598 | METHODS OF TREATING FIBROSIS | February 2023 | December 2025 | Allow | 34 | 1 | 0 | No | No |
| 18041911 | TOPICAL COMPOSITION | February 2023 | November 2025 | Allow | 33 | 1 | 0 | No | No |
| 17996867 | COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES | February 2023 | October 2025 | Allow | 36 | 0 | 1 | No | No |
| 18169296 | FOSPROPOFOL METHODS AND COMPOSITIONS | February 2023 | March 2025 | Allow | 25 | 1 | 0 | No | No |
| 18020774 | COMPOSITION FOR PREVENTION AND TREATMENT OF MYOPATHY | February 2023 | September 2025 | Allow | 31 | 0 | 0 | No | No |
| 18106616 | Food Safety Method | February 2023 | December 2024 | Allow | 22 | 1 | 0 | No | No |
| 18019527 | SALT INDUCIBLE KINASE INHIBITORS | February 2023 | November 2025 | Allow | 34 | 1 | 0 | No | No |
| 18155694 | METHODS AND COMPOSITIONS FOR USE OF THERAPEUTIC T CELLS IN COMBINATION WITH KINASE INHIBITORS | January 2023 | May 2025 | Abandon | 28 | 1 | 0 | No | No |
| 18155483 | METHODS OF TREATING HEART FAILURE WITH CARDIAC SARCOMERE ACTIVATORS | January 2023 | January 2025 | Allow | 24 | 1 | 0 | No | No |
| 18013355 | PROBENECID COMPOUNDS FOR THE TREATMENT OF INFLAMMASOME-MEDIATED LUNG DISEASE | December 2022 | November 2025 | Allow | 35 | 1 | 0 | No | No |
| 18012908 | METHOD AND COMPOUND FOR THE TREATMENT AND ELIMINATION OF AN IMMUNODEFICIENCY CONDITION | December 2022 | February 2026 | Abandon | 38 | 1 | 0 | No | No |
| 18012411 | WATER SOLUBLE 3-O-ACETYL-11-KETO-B-BOSWELLIC ACID AND METAL ION COMPOSITIONS, PROCESS FOR THEIR PREPARATION AND USES THEREOF | December 2022 | January 2026 | Allow | 37 | 1 | 0 | No | No |
| 18069555 | USE OF FERRIC CITRATE IN THE TREATMENT OF IRON-DEFICIENCY ANEMIA | December 2022 | February 2026 | Allow | 38 | 1 | 0 | No | No |
| 18002494 | METHOD OF ACHIEVING HIV VIRAL REMISSION USING LONG-ACTING ANTIRETROVIRAL AGENTS | December 2022 | January 2026 | Allow | 37 | 1 | 0 | No | No |
| 18083922 | COMPOSITIONS AND METHODS FOR INTRAVENOUS ADMINISTRATION OF 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHANONE | December 2022 | March 2025 | Allow | 27 | 1 | 0 | No | No |
| 18009306 | 2-OXO-OXAZOLIDINE-5-CARBOXAMIDES AS NAV1.8 INHIBITORS | December 2022 | September 2025 | Allow | 34 | 1 | 0 | No | No |
| 18000880 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OBSTRUCTIVE SLEEP APNOEA (OSA) | December 2022 | November 2025 | Allow | 36 | 1 | 0 | No | No |
| 18061985 | NEW TREATMENT OF SMA | December 2022 | March 2025 | Allow | 27 | 1 | 0 | No | No |
| 18008425 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | December 2022 | February 2026 | Allow | 38 | 1 | 1 | No | No |
| 18008005 | GLUCOKINASE ACTIVATOR FOR TREATING DIABETES WITH HEPATIC IMPAIRMENT | December 2022 | March 2026 | Abandon | 39 | 1 | 0 | No | No |
| 18073419 | STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES | December 2022 | February 2025 | Allow | 26 | 1 | 0 | No | No |
| 17986488 | SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY | November 2022 | December 2024 | Allow | 25 | 1 | 0 | Yes | No |
| 17921803 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANDROGRAPHOLIDE AND MELATONIN COMBINATION THERAPY | October 2022 | December 2025 | Allow | 38 | 1 | 0 | No | No |
| 17996812 | METHODS OF USING RHO KINASE INHIBITORS TO TREAT ALZHEIMER'S DISEASE | October 2022 | February 2025 | Allow | 28 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SHIAO, REI TSANG.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 42.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner SHIAO, REI TSANG works in Art Unit 1691 and has examined 192 patent applications in our dataset. With an allowance rate of 97.4%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 28 months.
Examiner SHIAO, REI TSANG's allowance rate of 97.4% places them in the 89% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by SHIAO, REI TSANG receive 1.19 office actions before reaching final disposition. This places the examiner in the 14% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by SHIAO, REI TSANG is 28 months. This places the examiner in the 67% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a -32.2% benefit to allowance rate for applications examined by SHIAO, REI TSANG. This interview benefit is in the 1% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 44.4% of applications are subsequently allowed. This success rate is in the 95% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 66.7% of cases where such amendments are filed. This entry rate is in the 90% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 96.3% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 21.9% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 4% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.